Ubs Group Ag Adagio Therapeutics, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 440,694 shares of ADGI stock, worth $1.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

440,694

Previous 387,363 13.77%

Holding current value

$1.46 Million

Previous $1.28 Million 13.73%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	N/A	53,331 Added 13.77%	440,694 $1.46 Million
Q4 2024 Feb 14, 2025	BUY	N/A	334,862 Added 637.82%	387,363 $1.28 Million
Q3 2024 Nov 14, 2024	BUY	N/A	28,397 Added 117.81%	52,501 $173,000
Q2 2024 Aug 13, 2024	BUY	N/A	22,736 Added 1661.99%	24,104 $79,000
Q1 2024 May 13, 2024	SELL	N/A	-13,089 Reduced 90.54%	1,368 $4,000
Q4 2023 Feb 09, 2024	BUY	N/A	13,308 Added 1158.22%	14,457 $47,000
Q3 2023 Nov 09, 2023	SELL	N/A	-435 Reduced 27.46%	1,149 $3,000
Q2 2023 Aug 11, 2023	SELL	N/A	-16,906 Reduced 91.43%	1,584 $5,000
Q1 2023 May 12, 2023	BUY	N/A	2,284 Added 14.09%	18,490 $61,000
Q4 2022 Feb 08, 2023	BUY	$3.08 - $4.05 $46,960 - $61,750	15,247 Added 1589.89%	16,206 $53,000
Q3 2022 Nov 10, 2022	SELL	$2.97 - $4.83 $397 - $647	-134 Reduced 12.26%	959 $3,000
Q2 2022 Aug 10, 2022	SELL	$2.54 - $4.52 $27,406 - $48,770	-10,790 Reduced 90.8%	1,093 $4,000
Q1 2022 May 16, 2022	SELL	$3.81 - $10.77 $318,839 - $901,287	-83,685 Reduced 87.57%	11,883 $54,000
Q4 2021 Feb 14, 2022	BUY	$6.35 - $47.04 $606,856 - $4.5 Million	95,568 New	95,568 $694,000

Others Institutions Holding ADGI

# of Institutions

Shares Held

67.4M

Call Options Held

31.6K

Put Options Held

54.3K

View Full List

About Adagio Therapeutics, Inc.

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

More about ADGI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account